Gossamer Bio (NASDAQ:GOSS) Announces Earnings Results, Misses Estimates By $0.18 EPS

Gossamer Bio (NASDAQ:GOSS) announced its quarterly earnings results on Thursday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.18), Fidelity Earnings reports.

Gossamer Bio stock traded down $0.13 during trading hours on Friday, hitting $19.38. 178,546 shares of the stock traded hands, compared to its average volume of 228,733. The business’s 50-day moving average price is $20.51. The company has a current ratio of 19.79, a quick ratio of 19.79 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.29 billion and a P/E ratio of -0.86. Gossamer Bio has a one year low of $15.59 and a one year high of $25.06.

Several research firms have weighed in on GOSS. Zacks Investment Research cut Gossamer Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. ValuEngine raised Gossamer Bio from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $28.00.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: Beige Book

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.